For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other clinical factors?
Community PollStarted
For patients with advanced endometrial cancer, do you ever opt to not give immunotherapy in the front-line in order to have another treatment option available in later lines?
84 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
Answered on
The standard of care for metastatic endometrial cancer is systemic therapy with chemotherapy and now with or without immunotherapy. With this approach to therapy, there is a roughly 70% reduction in the risk of progression or death across three separate trials for the dMMR population (RUBY, GY018, A...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · University of Iowa
Answered on
The addition of immunotherapy to chemotherapy should certainly be considered the standard of care for patients with dMMR tumors. At the 2023 ESMO meeting, Dr. @Dr. First Last and team made a compelling argument to further strengthen the use of immunotherapy in the front line. Using the RUBY patient ...
Join for free or sign in to see the full answer